Discovery of Medical Countermeasures Against Novel Entities

Discovery of Medical Countermeasures Against Novel Entities (DOMANE) is a program of the Defense Threat Reduction Agency (DTRA) intended to rapidly identify drugs and compounds for repurposing against emerging pathogens.¹⁾

DOMANE was created in 2019.²⁾ On December 11, 2019, the DTRA published a whitepaper outlining the project.³⁾

In early 2020, Michael Callahan alerted his colleague Robert Malone, then working as chief medical officer at Alchem Laboratories, of the emerging SARS-CoV-2 outbreak in Wuhan, China. Malone was also working on the DOMANE project, which identified several drugs approved by the Food and Drug Administration (FDA) that may work as potential treatments against COVID-19, the disease thought to result from infection with the virus.

One of the first drugs identified was Remdesivir, an experimental product developed by Gilead Sciences for use against Ebola.⁴⁾

Another candidate for repurposing was famotidine, commonly known as Pepcid.⁵⁾ On April 14, the Biomedical Advanced Research and Development Agency (BARDA) awarded Alchem a $20.7 million contract the conduct a clinical trial on the drug.

• Housatonic
• Wikipedia - redirects to Defense Threat Reduction Agency
• Wikispooks (Defense Threat Reduction Agency)